JOURNEY MEDICAL CORP (DERM) Stock Price & Overview

NASDAQ:DERM • US48115J1097

Current stock price

6.83 USD
-0.08 (-1.16%)
At close:
6.35 USD
-0.48 (-7.03%)
After Hours:

The current stock price of DERM is 6.83 USD. Today DERM is down by -1.16%. In the past month the price decreased by -21.72%. In the past year, price increased by 11.78%.

DERM Key Statistics

52-Week Range5.64 - 9.555
Current DERM stock price positioned within its 52-week range.
1-Month Range6.56 - 8.76
Current DERM stock price positioned within its 1-month range.
Market Cap
186.186M
P/E
N/A
Fwd P/E
26.52
EPS (TTM)
-0.58
Dividend Yield
N/A

DERM Stock Performance

Today
-1.16%
1 Week
-4.07%
1 Month
-21.72%
3 Months
-13.76%
Longer-term
6 Months -3.26%
1 Year +11.78%
2 Years +85.60%
3 Years +335.03%
5 Years N/A
10 Years N/A

DERM Stock Chart

JOURNEY MEDICAL CORP / DERM Daily stock chart

DERM Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to DERM. When comparing the yearly performance of all stocks, DERM is a bad performer in the overall market: 61.77% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

DERM Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to DERM. DERM may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

DERM Earnings

On March 25, 2026 DERM reported an EPS of -0.04 and a revenue of 16.08M. The company beat EPS expectations (31.8% surprise) and missed revenue expectations (-16.42% surprise).

Next Earnings DateN/A
Last Earnings DateMar 25, 2026
PeriodQ4 / 2025
EPS Reported-$0.04
Revenue Reported16.08M
EPS Surprise 31.80%
Revenue Surprise -16.42%

DERM Forecast & Estimates

10 analysts have analysed DERM and the average price target is 13.77 USD. This implies a price increase of 101.61% is expected in the next year compared to the current price of 6.83.

For the next year, analysts expect an EPS growth of 52% and a revenue growth 13.98% for DERM


Analysts
Analysts82
Price Target13.77 (101.61%)
EPS Next Y52%
Revenue Next Year13.98%

DERM Groups

Sector & Classification

DERM Financial Highlights

Over the last trailing twelve months DERM reported a non-GAAP Earnings per Share(EPS) of -0.58. The EPS increased by 41.41% compared to the year before.


Income Statements
Revenue(TTM)59.40M
Net Income(TTM)-8.66M
Industry RankSector Rank
PM (TTM) N/A
ROA -10.17%
ROE -33.45%
Debt/Equity 0.75
Chartmill High Growth Momentum
EPS Q2Q%47.06%
Sales Q2Q%20.52%
EPS 1Y (TTM)41.41%
Revenue 1Y (TTM)2.82%

DERM Ownership

Ownership
Inst Owners39.39%
Shares27.26M
Float20.18M
Ins Owners12.01%
Short Float %12.61%
Short Ratio21.43

DERM Latest News, Press Relases and Analysis

About DERM

Company Profile

DERM logo image Journey Medical Corp. is a commercial-stage pharmaceutical company, which focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company is headquartered in Scottsdale, Arizona and currently employs 41 full-time employees. The company went IPO on 2021-11-12. The firm is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.

Company Info

IPO: 2021-11-12

JOURNEY MEDICAL CORP

9237 E Via De Ventura Blvd., Suite 105, Suite 105

Scottsdale ARIZONA 94025 US

CEO: Thomas G. Wiggans

Employees: 41

DERM Company Website

DERM Investor Relations

Phone: 14804346670

JOURNEY MEDICAL CORP / DERM FAQ

What does JOURNEY MEDICAL CORP do?

Journey Medical Corp. is a commercial-stage pharmaceutical company, which focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company is headquartered in Scottsdale, Arizona and currently employs 41 full-time employees. The company went IPO on 2021-11-12. The firm is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.


Can you provide the latest stock price for JOURNEY MEDICAL CORP?

The current stock price of DERM is 6.83 USD. The price decreased by -1.16% in the last trading session.


Does DERM stock pay dividends?

DERM does not pay a dividend.


How is the ChartMill rating for JOURNEY MEDICAL CORP?

DERM has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


Can you provide the market cap for JOURNEY MEDICAL CORP?

JOURNEY MEDICAL CORP (DERM) has a market capitalization of 186.19M USD. This makes DERM a Micro Cap stock.


What is the ownership structure of JOURNEY MEDICAL CORP (DERM)?

You can find the ownership structure of JOURNEY MEDICAL CORP (DERM) on the Ownership tab.


Can you provide the short interest for DERM stock?

The outstanding short interest for JOURNEY MEDICAL CORP (DERM) is 12.61% of its float.